GlassScriptPhysician profile
Malinda Arrington
NPI 1750365698
$3,793.03
in general payments reported to CMS, 2019-2025
25 companies · $557 in 2025
The $557 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $902 · 2022: $616 · 2023: $804 · 2024: $913 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,274.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $405.46 | 2021-2024 | Airsupra, Andexxa, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $404.53 | 2023-2025 | |
| Abbvie INC. | $395.48 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.29 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $331.42 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $276.07 | 2021-2025 | |
| Exact Sciences Corporation | $262.44 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $217.30 | 2021-2022 | |
| Amgen INC. | $182.66 | 2021-2025 | Evenity |
| Glaxosmithkline, LLC. | $171.16 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Insulet Corporation | $161.32 | 2021-2024 | Omnipod |
| Novo Nordisk INC | $121.00 | 2022-2024 | Rybelsus, Wegovy, Ozempic |
| Mannkind Corporation | $114.79 | 2022 | |
| Boston Scientific Corporation | $55.23 | 2024-2025 | Watchman Flx |
| Harmony Biosciences LLC | $54.45 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $46.49 | 2023-2025 | |
| Abbott Laboratories | $37.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.07 | 2023-2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $33.43 | 2021 | |
| Xeris Pharmaceuticals, INC. | $31.84 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $25.96 | 2022 | |
| Pharmacosmos Therapeutics INC. | $16.30 | 2023 | Monoferric |
| Hologic Sales and Service, LLC | $15.31 | 2024 | Aptima, Thinprep 2000 Processor |
| Endo Pharmaceuticals INC. | $14.13 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malinda Arrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.